Surveyor Capital
Private equity
Active
Miami, United States
147
120M
121
9.19
8
0.17
51
- Areas of investment
Summary
Surveyor Capital appeared to be the VC, which was created in 2008.
Among the various public portfolio startups of the fund, we may underline Allogene Therapeutics, Annexon Biosciences, Oncorus The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Health Diagnostics, Pharmaceutical.
The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Surveyor Capital, startups are often financed by Skyline Ventures, SV Health Investors, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Alexandria Venture Investments, Samsara BioCapital. In the next rounds fund is usually obtained by Roche Venture Fund.
The top amount of exits for fund were in 2019. The top activity for fund was in 2019. This Surveyor Capital works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 50 - 100 millions dollars.
The overall number of key employees were 3.
Investor highlights
- Industry focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 147
- Lead investments
- 8
- Exits
- 51
- Rounds per year
- 9.19
- Follow on index
- 0.17
- Investments by industry
- Biotechnology (129)
- Health Care (82)
- Therapeutics (57)
- Pharmaceutical (46)
- Medical (41) Show 26 more
- Investments by region
-
- United States (126)
- Switzerland (4)
- China (4)
- United Kingdom (3)
- Canada (2) Show 4 more
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 48M
- Group Appearance index
- 1.00
- Avg. company exit year
- 6
- Avg. multiplicator
- 2.61
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Avalyn Pharma | 27 Sep 2023 | Biotechnology, Medical, Pharmaceutical, Biopharma | Late Stage Venture | 175M | United States, Washington, Seattle |
| Immuneering | 05 Jan 2021 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 62M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.